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Tuberculosis (TB) occurs in only 3e10% of Mycobacterium tuberculosis (Mtb) infected individuals, sug-
gesting that natural immunity can contain Mtb infection, although this remains poorly understood. Next
to T-cells, a potentially protective role for B-cells and antibodies has emerged recently. However, the Mtb
antigens involved remain ill-defined. Here, we investigated in a TB-endemic setting IgG levels against 15
Mtb antigens, representing various phases of Mtb infection and known to be potent human T-cell anti-
gens. IgG levels against ESAT6/CFP10, Rv0440, Rv0867c, Rv1737c, Rv2029c, Rv2215, Rv2389c, Rv3616c
and Mtb purified protein derivative (PPD) were higher in TB patients than in endemic and non-endemic
controls. The only exception was Rv1733c that was preferentially recognized by antibodies from endemic
controls compared to TB patients and non-endemic controls, suggesting a potential correlation with
control of TB infection and progression. In patients, IgG levels against Ag85B and Rv2029c correlated
with Mtb loads, while immunoglobulins against Rv0440 differed between genders. Our results support
the potential role of certain Mtb antigen-(Rv1733c) specific antibodies in the control of TB infection and
progression, while other Mtb antigen-specific antibodies correlate with TB disease activity and bacillary
loads. The findings for Rv1733c agree with previous T-cell results and have implications for including
antibody-mediated immunity in designing new strategies to control TB.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Humoral immunity has been generally considered not to play a
significant role in controlling infection by Mycobacterium tubercu-
losis (Mtb) [1], the facultative intracellular bacillus causing tuber-
culosis (TB), which causes 1.8 million deaths annually [2]. The
dominant T-cell-centric paradigm in TB is in line with the classical
view of a strict separation between antibody-mediated and cell-
mediated immunity directed against extracellular and intracel-
lular pathogens, respectively [3]. The elevated susceptibility to Mtb
in individuals with primary (genetic) or acquired (HIV) cellularLtd. This is an open access articleimmunodeficiencies [4,5] and the strong correlation of polyfunc-
tional CD4þ T cells with TB vaccine-induced protection in mice [6]
have contributed to that dogma. As a consequence our under-
standing of acquired immunity against TB and corresponding
strategies for the development of new candidate TB vaccines have
mainly focused on T cell responses [7]. However, it is now clear that
the presence ofMtb specific polyfunctional Tcells is not sufficient to
protect the human host against TB [8]. Moreover, a recent clinical
trial revealed that the frequency of polyfunctional T-cells in BCG/
MVA85 vaccinated individuals did not correlate with the presence
-or absence-of later development of TB disease in children [9,10].
In search of a better understanding of the complex immune
response against Mtb, several studies have evaluated B cells [11]
and immunoglobulin (Ig) responses in the context of Mtb infec-
tion [12]. Whereas the role of B cells is becoming increasinglyunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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host defense is under debate, although many serological studies
have reported the presence of antibodies duringMtb infection [15].
IgG titers against Mtb-specific proteins are detectable in immuno-
competent, latently Mtb-infected individuals as well as during
progression of active Mtb infection in TB-asymptomatic smear-
negative HIV-positive patients [16]. Additionally, a strong correla-
tion has been documented between the presence of specific anti-
Mtb lipoarabinomannan IgG responses and the absence of miliary
TB in a pediatric population, suggesting the possible involvement of
specific IgG in containing Mtb infection in infants [17]. This hy-
pothesis has been further supported by evidence that passive im-
munization with serum obtained frommice immunized with RUTI,
a therapeutic TB vaccine, limited the presence of the bacilli to the
lungs ofMtb-infected severe combined immunodeficient mice [18].
Furthermore, many studies observed that severalMtb antigens able
to confer TB protection in mice and non-human primates elicited
specific mycobacterial antibodies not induced by natural Mtb
infection [19e21]. In addition, the potential protective role of
antibody responses has also been suggested by the association of
Ag85A-specific IgG boosted by MVA85A vaccination in adolescents
with a significantly reduced risk of developing TB [22].
Collectively these results suggest a potential contribution ofMtb
antigen specific antibodies to protection from TB disease. Various
mechanisms may be involved [23] which include: opsonization,
which may increase Mtb uptake and intracellular killing [24];
amelioration of T-cell activation, through an increased secretion of
pro-inflammatory cytokines [24]; enhanced antigen presentation
to CD4 T cells [25]; activation of the complement cascade (7); the
formation of immuno complexes that target Mtb antigens and
activate DCs through FcR ligation [26]; the glycosylation of the
constant (Fc) domains that control the balance between pro- and
anti-inflammatory antimicrobial responses [27] via up-regulated
Fcg receptor expression [28] by dendritic cells and macrophages
[29]; the initiation of innate immune signaling through the acti-
vation of intracellular receptors such as TRIM21 [30].
In search of better TB diagnostics and new TB vaccine candi-
dates, many innovative strategies have been applied to discover the
Mtb antigenome responsible for eliciting human cellular immunity
[31]. Mtb dormancy regulon (DosR regulon) encoded proteins as
well as resuscitation promoting factor (Rpf) proteins have been
associated with Mtb latency and found to be recognized by CD4þ
and CD8þ T-cells in Mtb-infected individuals. Genome-wide unbi-
ased antigen discovery approaches used pulmonary in vivo Mtb
gene expression profiles in mice infected with Mtb, to identify IVE-
TB antigens, stimulating T-cell responses in latently Mtb-infected
individuals [32,33]. While all these groups of antigens have been
extensively evaluated for their ability to induce T cell responses
across many different human populations, these studies were often
not complemented by serological analyses. Therefore, we decided
to evaluate IgG responses against PPD and a selection of specific
Mtb antigens, based on our previous antigen discovery work. The
antigens studied here included: Mtb DosR regulon-encoded pro-
teins (Rv1733c, Rv1737c and Rv2029c) [34], Mtb resuscitation-
promoting factors (Rv0867c and Rv2389) [35], IVE-TB antigens
(Rv0440, Rv0645c, Rv1980c, Rv2031, Rv2215, Rv2626c, Rv3407 and
Rv3616c) [33] and Mtb antigens related to active growth (ESAT-6/
CFP10 and Ag85B) [36,37].
2. Materials and methods
2.1. Study design and sample collection
A total of 116 stored samples collected between 2005 and 2014
were used in the present study; these were obtained from theUniversity of Antioquia and included subjects previously recruited
in Medellin, Colombia. Individuals were either smear-positive pa-
tients experiencing active pulmonary tuberculosis (TB; n ¼ 85: 77
patients had no or <1 month anti-TB chemotherapy, 7 patients 1e2
months of treatment, and 1 patient > 3 months) or healthy in-
dividuals from the same endemic area with known (n ¼ 15) or
unknown TB (n ¼ 16) exposure. Humoral responses in these two
endemic groups did not differ significantly such that these were
combined into a single endemic control group (EC; n ¼ 31). Sera
from a group of non-endemic Dutch controls (NEC; n ¼ 25) were
included in the study. The Dutch controls were individuals with a
negative Mantoux tuberculin skin test (TST) (<15 mm) and
QuantiFeron-TB Gold IneTube test (QFT-GIT) (Cellestis, Carnegie,
VIC, Australia) (0.3 IU/ml). None of the donors included in this
study had comorbidities (HIV-infection, diabetes or cancer) at the
time of recruitment.
The study protocols P207/99 and P07/048 were approved by the
institutional review board of Leiden University Medical Center, The
Netherlands, and by the Ethics Committee of the Instituto de
Investigaciones Medicas of the Facultad de Medicina, Universidad
de Antioquia. Medellín, Colombia and the local Colombian health
authorities (Direccion Seccional de Salud de Antioquia and the
Secretaría de Salud de Medellín), respectively.
2.2. Mycobacterial stimuli
Mtb DosR regulon-encoded proteins (Rv1733c, Rv1737c and
Rv2029c), resuscitation-promoting factors (Rv0867c and Rv2389),
IVE-TB antigens (Rv0440, Rv0645c, Rv1980c, Rv2031c, Rv2215,
Rv2626c, Rv3407 and Rv3616c) and Mtb active growth phase an-
tigens (ESAT-6/CFP10 fusion protein and Ag85B) were used in this
study. HPV16E6 was included as a negative recombinant control.
Recombinant production and quality control were performed as
previously described [33].Mtb purified protein derivative (PPD) RT-
50 (Statens Serum Institut, Copenhagen, Denmark) was also
included in the screening.
2.3. Quantitation of serum IgG antibody responses
Total IgG responses were measured by ELISA [21]. Microlon®
high binding 96-well plates were coated for 2 h at 37 C with PPD,
recombinant proteins (5 mg/ml) or PBS 0.4% Bovine Serum Albumin
(BSA) used as blank. After removing unbound proteins using
washing buffer (PBS containing 0.05% Tween-20), plates were
blocked for an hour at 37 Cwith blocking buffer (PBS containing 1%
BSA and 1% Tween-20). After washing plates three times, diluted
samples (1:400) were added to the wells and incubated overnight
at 4 C. Then, plates were rinsed six times with washing buffer and
incubated with polyclonal rabbit anti-human total IgG/HRP (P0214
Dako, Glostrup, Denmark). After 2 h at 37 C, plates were washed
four times, and tetramethylbenzidine substrate (TMB; Sigma) was
added and incubated for 15 min in the dark at room temperature.
By adding H2SO4, the reaction was stopped, and absorbance was
measured using a BioRad Microplate Reader 680 (BioRad Labora-
tories, Veenendaal, The Netherlands) at 450 nm. The blank median
optical density (OD450), which ranged 0.05e0.11 in TB, 0.05e0.07 in
the EC and 0.05e0.08 in the NEC, was subtracted for each sample to
avoid background influence.
2.4. Statistical analysis
Statistical analysis was performed using GraphPad Prism
(version 6.0). The ManneWhitney test was used to compare the
difference between groups of donors based on the IgG antibody
levels measured as OD450 induced by stimulationwith the antigens
Table 1
Characteristics of tuberculosis (TB) patients included in the study.
Characteristics TB Patients (n ¼ 85)
Age, y, median (range) 34 (16e73)
Male sex 44/85





Days of treatment, median (range) 9 (0e155)
TB recurrences 14/85
BCG: Bacillus Calmette Guerin.
Table 2
Characteristics of Healthy Controls (HC) Included in The Study.
Characteristics HC
EC NEC
(n ¼ 31) (n ¼ 25)
Age, y, median (range) 29 (19e65) 38 (27e62)
Male sex 12/31 8/25
Presence of BCG scar 12/14 2/25
TST positive* 8/8 0/16
EC: endemic controls; NEC: non-endemic controls; BCG: Bacillus Calmette Guerin;
TST: tuberculin skin test. HC: healthy controls; TB: tuberculosis patients.
*: induration of 15 or more millimeters.
Fig. 1. Cumulative IgG responses to Mycobacterium tuberculosis (Mtb) antigens.
Box-and-whisker plots feature individual dots that correspond to the optical density
(OD) values measured in response to all 15 Mtb antigens included in this study (A) and
PPD (B). Values are shown for sera from 85 TB patients (TB), 31 endemic controls (EC)
and 25 non-endemic controls (NEC). The background was subtracted from all samples.
A p-value of 0.05 was considered significant. Significance levels are indicated as
M. Coppola et al. / Tuberculosis 106 (2017) 25e32 27or PPD. A p value less than 0.05 was considered statistically
significant.
3. Results
3.1. Differences in Mtb specific IgG responses to infection phase
related Mtb specific protein antigens in subjects exposed or not to
Mtb
IgG levels against 15 Mtb recombinant protein antigens, previ-
ously shown to induce significant T cell responses in latently TB
infected individuals (LTBI) were measured in 141 sera by ELISA.Mtb
PPD was used as a positive control antigen. Sera were obtained
from Colombian patients with active (pulmonary) tuberculosis (TB)
(n¼ 85), Colombian endemic controls (EC) (n¼ 31) and Dutch non-
endemic controls (NEC) (n ¼ 25) (Tables 1 and 2). Differences
among donor groups were evaluated by the ManneWhitney test.
Combining the IgG levels against the 15 phase related Mtb
specific protein antigens, TB patients showed a higher humoral
response than EC and NEC (p ¼ 0.0378 and < 0.0001, respectively).
A significant difference (p¼ 0.0015) was also observed between the
total levels of antibodies produced by EC and NEC (Fig. 1A). A highly
significant difference was observed in anti-tuberculin IgG antibody
levels between TB patients and EC (p < 0.0001), between TB pa-
tients and NEC (p < 0.0001), and between EC and NEC (p < 0.0017)
(Fig. 1B). Similarly, high serum levels of anti-ESAT6/CFP10 IgG an-
tibodies were found in TB patients compared to EC (p < 0.0001) and
NEC (p < 0.0001) (Fig. 2A). However, no differences were found
between EC and NEC, suggesting that the observed differences in
PPD specific IgG between EC and NEC might be due to exposure to
non-tuberculous, cross-reactive mycobacterial antigens, present in
PPD but absent from ESAT6/CFP10 protein. Although less signifi-
cant, the IgG responses detected against Rv3616c resembled the
trend described for ESAT6/CFP10 (TB vs. EC: p¼ 0.0243; TB vs. NEC:
p ¼ 0.0340) (Fig. 2B). In addition, serum IgG levels against other
Mtb antigens were found to be higher in TB patients than in EC
(Rv0867c) and NEC (Rv0440, Rv1737c, Rv2029c, Rv2215, Rv2389c,
Rv3616c) and were also higher in EC than in NEC (Rv0440, Rv1733c,
Rv1737c, Rv2389c) (Table 3). Notably, IgG antibody levels against
one latency antigen, Rv1733c, were highest in the EC compared to
the TB group and NEC (p < 0.0001) (Fig. 2C). This is interesting as T
cell responses against Rv1733c are normally higher in LTBI than TB
patients, in contrast to ESAT6/CFP10. No differences between the
groups were observed in the total IgG levels against HPV16E6, used
as unrelated control antigen (Fig. 2D), or against the other Mtb
antigens tested (Ag85B, Rv0645c, Rv2031c, Rv2626c and Rv3407)
(Table 3).
3.2. IgG responses to specific Mtb antigens differ between TB
patients by gender and clinical characteristics
The IgG responses detected within the TB patient group wereanalyzed in more detail with respect to age, gender, evidence of
BCG scar and clinical characteristics reported at recruitment
(Table 2). Interestingly, IgG levels against Rv0440 were higher in
males than in females (p ¼ 0.0193), suggesting a significant influ-
ence of gender on the humoral immune response against this an-
tigen (Fig. 3A). In addition, individuals with a high number of acid-follows: *: p ¼ 0.01e0.05; **: p ¼ 0.001e0.01; ***: p ¼ 0.0001e0.001; ****: p  0.0001.
Fig. 2. Antibody responses to specific Mtb antigens and PPD. Box-and-whisker plots include individual dots that correspond to the optical density (OD) values measured in
response to the following antigens: (A) ESAT6/CFP10 (E/C), (B) Rv3616c, (C) Rv1733c, (D) HPV16E6. (A), (B), (C), and (D) show values with background subtracted. Significance
differences were evaluated between 85 TB patients (TB), 31 endemic controls (EC) and 25 non-endemic controls (NEC). Significance levels are indicated as follows: *: p ¼ 0.01e0.05;
**: p ¼ 0.001e0.01; ***: p ¼ 0.0001e0.001; ****: p  0.0001.
Table 3
Comparison of specific IgG antibody levels between TB patients, Endemic Controls (EC) and Non-Endemic Controls (NEC).
Fig. 3. Antibody responses to specific Mtb antigens in TB patients with diverse demographic and clinical characteristics. Box-and-whisker plots include individual dots that
correspond to the optical density (OD) values measured in response to the following antigens: Rv0440, Ag85B, Rv2029c, ESAT6/CFP10 (E/C), Rv3616c and PPD. Different de-
mographic and clinical characteristics were compared in TB patients: (A) gender, (B) bacterial load and (C) TB cases with recurrent (TB recurrent) or new diagnosed disease (new
TB). Significance levels were indicated as follows: *: p ¼ 0.01e0.05; **: p ¼ 0.001e0.01; ***: p ¼ 0.0001e0.001; ****: p  0.0001.
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tended to have increased levels of IgG antibodies against Rv2029c
and Ag85B compared to patients with lower numbers of detectable
bacilli (>10 vs. 5e10 bacilli; Rv2029: p ¼ 0.0194; >10 vs. 5e10
bacilli; Ag85B: p ¼ 0.0186; >10 vs 1e5 bacilli; Ag85B: p ¼ 0.0002)
(Fig. 3B). This was not the case for ESAT6/CFP10 or PPD (Fig. 3).
Moreover, TB cases with an actual recurrence episode had higher
levels of IgG to ESAT6/CFP10 and Rv3616c than the cases experi-
encing the first episode of pulmonary TB (ESAT6/CFP10: p¼ 0.0177;
Rv3616c: p¼ 0.0481) (Fig. 3C). Age, days of treatment and presenceof BCG scar did not appear to have any influence on specific IgG
levels.
4. Discussion
Although the role of humoral immunity in tuberculosis (TB) is
widely debated, an increasing number of studies has proposed B
cells and antibodies as significant components of the immune
response against Mycobacterium tuberculosis (Mtb) [11,23]. The
improved containment of TB through passive transfer of immune
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by monoclonal immunoglobulins [38], the increased TB suscepti-
bility in human hosts with antibody deficits [17], the association of
Mtb antigen directed antibody titres with reduced Mtb loads in
animals [19e21] and with reduced TB risk in BCG/MVA85A vacci-
nated infants [22], and the expansion of in vitro studies suggesting a
microbicidal role of certain PPD directed antibodies [24,27] all tend
to lend support to the hypothesis that humoral-mediated immu-
nity might contribute to an overall protective response to Mtb.
As mentioned above, many Mtb antigens have been discovered
by different strategies [39] focusing on analysing T cell responses,
but these studies rarely included antigen recognition by antibodies.
We therefore decided to investigate the presence of IgG antibodies
against 15 Mtb antigens representing different stages of Mtb
infection: ESAT-6/CFP10 and Ag85B generally representing the
active Mtb replication stage [36,37]; Rv1733c, Rv1737c and
Rv2029c, representing Mtb DosR regulon-encoded proteins [34];
Rv0867c and Rv2389, two resuscitation-promoting factors,
expressed duringMtb reactivation [35]; Rv0440, Rv0645c, Rv1980c,
Rv2031, Rv2215, Rv2626c, Rv3407 and Rv3616c which genes are
up-regulated during in vivo Mtb pulmonary infection in mice [33].
As described in other studies [40,41], Mtb specific antibody
levels were significantly higher in TB patients than in EC and NEC.
The IgG response to each Mtb antigen mostly followed the trend of
higher IgG levels correlating with higher Mtb exposure. To our
knowledge, five antigens (Rv0645, Rv2215, Rv2626c, Rv3407 and
Rv3616c) were studied here for the first time in the context of
humoral TB immunity. The other Mtb stimuli (PPD, ESAT6/CFP10,
Ag85B, Rv0440, Rv0867c, Rv1733c, Rv1737c, Rv1980c, Rv2029c,
Rv2031c and Rv2389c) have been evaluated in other serological
studies [40e46], which also showed higher IgG antibody levels
against specific antigens in TB patients than in the control groups.
Out of the 15 Mtb phase related antigens screened, nine showed a
different humoral profile between the groups analyzed. Except for
one (Rv2215), all the antigens recognized by antibodies are known
to be secreted proteins or to have predicted transmembrane re-
gions (according to Tuberculist: http://tuberculist.epfl.ch/). IgGs
against two (Rv2215 and Rv3616c) out of the five antigens that
were originally included here were also increased in TB patients
compared to controls. Our results for ESAT6/CFP10 and Rv0867c are
in agreement with previous reports [40,42,44,46]. Although for
Rv2029c, Rv1737c and Rv2389c we could not confirm a significant
difference between the antibody levels in TB patients and EC, as
recently observed in a Brazilian cohort [46], we nevertheless found
increased IgG antibody levels in TB compared with NEC. While
controversial results have already been reported on the humoral
response against Ag85B and Rv1980c [15,40e43], IgG antibodies
against Rv2031c have been mostly described to be increased in TB
patients [15,42,44,45]. In line with some of these studies but in
contrast to others, Rv1980c-, Rv2031c- and Ag85B-specific IgG
levels did not show any differences between the groups in our
cohort. The slightly different serological antigen recognition profile
we find compared to other studies is not surprising. Variation in
antibody responses has already been extensively discussed previ-
ously, and has been ascribed to multiple factors, including the
different immunogenetic backgrounds of infected hosts; the
expression and production of diverse mycobacterial antigens dur-
ing multiple stages of Mtb infection; different antigen recognition
patterns in different individuals by genetically restricted T helper
cells, which contribute to the induction of antibodies [42], as well
as microbiota- and NTM-exposure related factors. Moreover, poly-
morphisms that might occur in B cell epitopes regions [23] could
also contribute to the wide variability found here and in other re-
ports. This has been suggested for Rv1980 by two studies [47,48],
which showed a high rate of mutations affecting the B cell epitopesrepertoire of that antigen in clinical isolates.
Interestingly, the only exception was antigen Rv1733c to which
specific IgG antibody levels were found to be significantly higher in
EC than in both TB patients and NEC. The EC group is likely to have
been exposed to Mtb in the past [36], and the pattern of IgG levels
agrees well with the T cell signature that has repeatedly been
observed against this latency antigen: Rv1733c is preferentially
recognized by T cells from LTBI individuals compared to TB patients
in both EU, African, South American populations as well as in India
(unpublished) [34,35]. In other work we have also shown that NTM
can induce higher IFN-g response against Rv1733c in NTM-exposed
donors than in unexposed controls [49]. Therefore, it was not un-
expected to find increased anti-Rv1733 IgGs in the EC group
considering the endemic setting of the study population where
both Mtb and NTM are present. In any case, the higher levels of
Rv1733c antibodies and the difference found between the EC and
the other groups are relevant as this data suggest Rv1733c specific
antibodies levels are associated with control of TB infection and
progression. We have also found high titers of antibodies in HLA-
DR3 transgenic mice after immunisation with a multistage-
polyepitope vaccine containing a Rv1733c epitope, or with a long
synthetic peptide both derived from Rv1733c [20,21]. To our
knowledge, only one other study has evaluated the anti-Rv1733 IgG
in another endemic cohort [46], however, this did not reveal the
same trend as we describe here. The different outcome could be
attributed to the different IgG isotypes analyzed (IgG1 vs. total IgG),
the different readout used (ELISA index vs. OD450), differences in
study populations and differences in infection levels. Our obser-
vations provide a lead towards further studies addressing the
precise role of Rv1733c specific antibodies in TB infection.
Of note, the levels of antibodies measured were higher for PPD
and ESAT6/CFP10 than for any other Mtb antigen. As discussed for
other pathogens [50], however, more might not be necessarily
better in qualitative terms: higher levels of antibodies could be
paradoxically less protective than lower levels, contributing to the
so-called ‘prozone-like effect.' For TB, the high levels of anti-
tuberculin IgG found not only in TB patients but also in high-risk
TB contacts is in line with such a theory [51,52]: in contrast to
donors with low tuberculin antibody titers, sera from individuals
with high PPD-IgG titers were found to modulate the proliferative
activity of the PBMCs of autologous donors either by increasing or
blocking PBMC stimulation. Additionally, it has been found previ-
ously that in active TB disease the expression of the high-affinity
IgG receptor (FCGR1A) is higher than in LTBI, which could suggest
a significant contribution of antibodies to TB pathogenesis [28].
Although the size of the groups compared in the present study
was relatively small, cases with recurrent TB had higher levels of
antibodies against ESAT6/CFP10 and Rv3616c, while antibody levels
against Ag85B and Rv2029c were associated with bacterial load at
the time of recruitment, confirming a trend reported previously
[44]. Examining the correlation of clinical information with the
antibody production in the TB group, we also found that anti-
Rv0440 IgG levels differed according to gender, confirming the
trend in a previous study inwhich the levels of antibodies against a
set of Mtb-specific antigens were higher in males than in females
[53]. This result could be influenced also by other factors, such as an
increased antigen load due to a more severe disease in one of the
two groups. This effect could not be assessed due to a lack of in-
formation regarding the disease severity of the patients enrolled.
Antibodies against Rv0440 have also been observed in other
pathological conditions such as in the progression of inflammatory
[54] and autoimmune diseases [55]. For instance, IgG against
Rv0440 has been suggested to be protective against adjuvant-
induced arthritis, whose related human pathology is more
frequent in females than males [56]. Underlying gender-dependent
M. Coppola et al. / Tuberculosis 106 (2017) 25e32 31pathogenic and pathophysiological processes could be of broader
relevance to other diseases as well.
Our study had several limitations. First of all, the small size of
the groups limits the impact of our conclusions, especially on the
demographic parameters. We could not evaluate the impact of
helminth infection on the measured IgG levels, although that
condition is recognized to affect either humoral or cellular immu-
nity toMtb [57]. Moreover, we investigated only the total amount of
IgG antibodies against specific Mtb antigens but not the contribu-
tion of each IgG isotype, the antibody avidity or the different
glycosylation patterns present in the Fc portion of the immuno-
globulins detected [12,27], which could have given more insights
into the antibodies functionality.
In conclusion, our collective findings support the need to further
investigate and understand the pleiotropic effect of antibodies in
the immune response toMtb, their influence onTB disease outcome
and their possible contribution to control Mtb infection.
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